WAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Should You Sell?

Key Points

• WAVE shares crossed below its 50-day moving average, trading as low as $7.24 and last at $7.31 versus a 50-day MA of $10.60, on volume of about 2.56 million shares.
• Analysts remain broadly positive with a consensus “Moderate Buy” and an average price target of $30.63 despite the company reporting a Q EPS loss of $0.30 (missing estimates) and a sharply negative net margin.
• Insiders sold 52,373 shares in the last quarter (roughly $757,527), while institutional investors hold a substantial portion of the stock, indicating mixed owner activity around recent weakness.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $10.60 and traded as low as $7.24. WAVE Life Sciences shares last traded at $7.31, with a volume of 2,563,425 shares trading hands.

Wall Street Analyst Weigh In

WVE has been the topic of a number of research analyst reports. Truist Financial upgraded WAVE Life Sciences to a "strong-buy" rating in a research note on Wednesday, March 25th. Bank of America cut their price objective on WAVE Life Sciences from $38.00 to $21.00 and set a "buy" rating for the company in a report on Friday, March 27th. Mizuho raised their target price on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, March 25th. Cantor Fitzgerald lifted their target price on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Finally, Wedbush boosted their price target on shares of WAVE Life Sciences from $33.00 to $35.00 and gave the stock an "outperform" rating in a research note on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $30.63.

WAVE Life Sciences Stock Performance

The company has a market cap of $1.38 billion, a PE ratio of -5.99 and a beta of -1.32. The business's 50-day moving average is $10.60 and its 200 day moving average is $11.23.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The business had revenue of $17.25 million for the quarter, compared to analysts' expectations of $15.68 million. Equities research analysts anticipate that WAVE Life Sciences Ltd. will post -1.39 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Chris Francis sold 33,194 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $15.05, for a total transaction of $499,569.70. Following the completion of the sale, the insider directly owned 61,867 shares in the company, valued at $931,098.35. This represents a 34.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kyle Moran sold 3,588 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $48,258.60. Following the transaction, the chief financial officer owned 134,385 shares in the company, valued at approximately $1,807,478.25. The trade was a 2.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 52,373 shares of company stock valued at $757,527. 23.98% of the stock is owned by insiders.

Institutional Investors Weigh In On WAVE Life Sciences

Several institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its position in shares of WAVE Life Sciences by 6,729.0% in the fourth quarter. CWM LLC now owns 2,117 shares of the company's stock valued at $36,000 after acquiring an additional 2,086 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of WAVE Life Sciences by 645.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company's stock worth $38,000 after purchasing an additional 1,942 shares during the last quarter. Bessemer Group Inc. increased its holdings in WAVE Life Sciences by 1,156.3% during the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company's stock valued at $72,000 after purchasing an additional 9,135 shares during the period. Russell Investments Group Ltd. raised its position in WAVE Life Sciences by 1,441.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company's stock valued at $73,000 after purchasing an additional 9,284 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in WAVE Life Sciences by 44.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company's stock valued at $76,000 after purchasing an additional 3,609 shares during the last quarter. Hedge funds and other institutional investors own 89.73% of the company's stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.